| HOME >> MEDICINE >> TECHNOLOGY |
Figure 4.11: Timeline of GPCR 3-dimensional structural information 58
Figure 4.12: Potential advantages with allosteric modulators of GPCR function 62
Figure 4.13: Schematic of allosteric modulator approach 63
Figure 4.14: Comparison of biased ligands and conventional GPCR ligands 69
Figure 5.15: Approach to more selective antipsychotic drugs 76
Figure 5.16: Lorcaserin, enhanced 5-HT2C receptor selectivity 78
Figure 7.17: Continued opportunities to exploit GPCRs 109
Figure 7.18: Angiotensin AT1 antagonists - the patent cliff in the US 113
List of Tables
Table 1.1: Classes of GPCRs 19
Table 1.2: Sales of GPCR-directed drugs achieving sales of >$250m in 2009 24
Table 3.3: Sales of AT1 receptor antagonists ($m), 2009 42
Table 5.4: GPR119 agonists in development for the treatment of type 2 diabetes 82
Table 5.5: DP2 antagonists in development for the treatment of asthma 83
Table 6.6: GPCR pipeline of 7TM Pharma 93
Table 6.7: GPCR pipeline of Actelion 94
Table 6.8: GPCR pipeline of Addex Pharmaceuticals 96
Table 6.9: GPCR pipeline of Arena Pharmaceuticals 97
Table 6.10: GPCR pipeline of Domain Therapeutics 101
Table 6.11: GPCR pipeline of Euroscreen 102
Table 6.12: GPCR pipeline of Tranzyme Pharma 105
Table 7.13: Drugs in advanced development, targeting unexploited GPCRs 115
Companies mentioned
To order this report:
Drug Discovery and Development Industry: The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |